Merck Stock News

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.

Merck plans to buy biotech Harpoon Therapeutics. Harpoon's platform is powerful, and it could produce many opportunities.

Merck (MRK) concluded the recent trading session at $119.43, signifying a +0.45% move from its prior day's close.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1.

Within the dividend stock portfolio, there is a case for finer diversification. First, there are blue-chip dividend stocks with stable cash flows and relatively muted dividend growth.

The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in combination with chemoradiotherapy to treat newly diagnosed patien

Investing in the best blue-chip stocks offers some benefits, especially lower volatility. Typically, these stocks are stable companies with a lower beta than their peers.

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-

Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.

Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript)

Merck (MRK) reachead $117.38 at the closing of the latest trading day, reflecting a +0.14% change compared to its last close.

How To Build A Dividend Growth Portfolio As A 'Young Investor' With $100,000

The shares of Merck & Co Inc (NYSE:MRK) are already 7.3% higher since the start of the year, and earlier hit a six-month high of $117.89 before turning lower.

Shares of Harpoon Therapeutics Inc. (HARP) more than doubled Monday after Merck & Co. (MRK) agreed to buy the cancer drug researcher for about $680 million.